文献速递产科母胎医学

剖宫产后试产中缩宫素最大剂量与子宫破裂的关联

Maximum Oxytocin Dose and Uterine Rupture During Trial of Labor After Cesarean.
PubMed 文献 · Obstet Gynecol · 2025-10-30

本研究为美国25家医院2008-2011年剖宫产后试产(TOLAC)观察性队列的二次分析,纳入5201例单胎头位活产、一次剖宫产史者。发现使用缩宫素(无论低剂量1-20或高剂量>20毫国际单位/分钟)相较于未使用,子宫破裂风险显著升高,但高剂量与低剂量相比未进一步增加破裂风险,未能确定缩宫素最大剂量的安全上限。

要点

  • 与未用缩宫素相比,最大剂量1-20和>20毫国际单位/分钟均与子宫破裂风险升高相关。
  • 高剂量(>20)与低剂量(1-20)相比,子宫破裂风险无显著差异。
  • 缩宫素最大剂量连续分析每增加5毫国际单位/分钟,子宫破裂风险升高。

核心结论

  • 使用缩宫素(低剂量或高剂量)相较于未使用,与子宫破裂风险升高相关,但也与成功VBAC相关。
  • 高剂量(>20毫国际单位/分钟)与低剂量(1-20毫国际单位/分钟)相比,未发现子宫破裂风险显著增加。
  • 未能确定缩宫素最大剂量的安全上限。

研究设计与样本

  • 研究为Eunice Kennedy Shriver NICHD MFMU Network Assessment of Perinatal Excellence研究的二次分析。
  • 观察性队列纳入2008至2011年美国25家医院、孕23周后分娩者。
  • 纳入标准:单胎、头位、活产、一次剖宫产史、尝试TOLAC(包括自然临产、加强宫缩或引产)。
  • 排除TOLAC禁忌、胎儿畸形或已知遗传异常者。
  • 共纳入5201例TOLAC个体。

主要发现

  • 缩宫素最大剂量分布:0毫国际单位/分钟3406例(65.5%),1-20毫国际单位/分钟1659例(31.9%),>20毫国际单位/分钟136例(2.6%)。
  • 最大剂量范围为0-60毫国际单位/分钟。
  • 子宫破裂共37例(0.7%,95% CI 0.5-0.9%)。
  • 子宫破裂频率:0剂量组0.2%(n=7),1-20组1.6%(n=27),>20组2.2%(n=3)。
  • Cochran-Armitage趋势检验显示最大缩宫素剂量越高,子宫破裂趋势增加(P<.001)。

关键数值与推荐

  • 调整后模型:与0毫国际单位/分钟相比,1-20毫国际单位/分钟组子宫破裂aOR 8.82(95% CI 3.61-21.6),>20毫国际单位/分钟组aOR 11.0(95% CI 2.67-45.3)。
  • 与1-20毫国际单位/分钟相比,>20毫国际单位/分钟组子宫破裂aOR 1.25(95% CI 0.37-4.22)。
  • 连续变量分析:最大缩宫素剂量每增加5毫国际单位/分钟,子宫破裂aOR 1.40(95% CI 1.21-1.62)。
  • 最大缩宫素剂量与输血或ICU入住无关。

临床怎么用

  • TOLAC中使用缩宫素需权衡子宫破裂风险与VBAC成功率。
  • 低剂量和高剂量缩宫素均与子宫破裂风险升高相关,但高剂量未较低剂量进一步增加风险。
  • 缩宫素使用时间及最大剂量维持时间延长与子宫破裂风险升高相关,应尽量缩短暴露时间。
  • 无法依据最大剂量确定安全上限,临床决策需个体化。

局限性

  • 本研究为观察性队列的二次分析,可能存在残余混杂。
  • 高剂量组(>20毫国际单位/分钟)样本量小(n=136),事件数少(n=3),估计精度有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To evaluate the association between maximum oxytocin dose and uterine rupture among individuals undertaking a trial of labor after cesarean (TOLAC). Secondarily, to evaluate the association between total time on oxytocin and time at maximum oxytocin dose and uterine rupture. METHODS: We conducted a secondary analysis of the Eunice Kennedy Shriver National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network Assessment of Perinatal Excellence study, an observational cohort of deliveries after 23 weeks of gestation across 25 U.S. hospitals from 2008 to 2011. Individuals with a singleton, cephalic, live fetus who had one prior cesarean delivery and were undertaking TOLAC, including those undergoing spontaneous, augmented, or induced labor, were included. Those with a contraindication to TOLAC or a fetus with an anomaly or known genetic abnormality were excluded. The exposure was intrapartum oxytocin dose in milli-international units per minute (milli-international units/min), assessed both categorically (0, 1-20, more than 20 milli-international units/min) and continuously. The primary outcome was uterine rupture. Secondary outcomes were vaginal birth after cesarean (VBAC), blood transfusion, and intensive care unit (ICU) admission. Trends in outcomes by oxytocin were assessed using the Cochran-Armitage trend test. Multivariable modeling estimated the association between maximum oxytocin dose (both as a categorical and continuous variable) and outcomes. The duration of any oxytocin, the duration at the maximum dose of oxytocin, and outcomes were assessed. RESULTS: Of 5,201 individuals undergoing TOLAC, 3,406 (65.5%) received 0 milli-international units/min of oxytocin, 1,659 (31.9%) received 1-20 milli-international units/min, and 136 (2.6%) received more than 20 milli-international units/min. The majority of the cohort (n=3,391) entered spontaneous labor; 1,076 patients received augmentation and 733 were induced. The range of maximum oxytocin doses was 0-60 milli-international units/min. There were 37 cases of uterine rupture (0.7%, 95% CI, 0.5-0.9%). The frequency of uterine rupture by maximum oxytocin dose category was 0.2% (n=7) with no oxytocin (0 milli-international units/min), 1.6% (n=27) with an oxytocin dose of 1-20 milli-international units/min, and 2.2% (n=3) with oxytocin doses greater than 20 milli-international units/min. Higher maximum oxytocin doses were associated with a trend of an increase in uterine rupture (P<.001 Cochran-Armitage test of trend). In adjusted modeling, maximum oxytocin doses of 1-20 milli-international units/min and doses greater than 20 milli-international units/min were associated with uterine rupture (adjusted odds ratio [aOR] 8.82, 95% CI, 3.61-21.6; and aOR 11.0, 95% CI, 2.67-45.3, respectively), compared with 0 milli-international units/min; however, a higher maximum dose (more than 20 milli-international units/min) was not associated with uterine rupture (aOR 1.25, 95% CI, 0.37-4.22) when compared with a lower maximum dose of oxytocin (1-20 milli-international units/min). When analyzed as a continuous variable, a higher maximum oxytocin dose was associated with higher odds of uterine rupture (aOR 1.40 for each 5 milli-international units/min higher dose of oxytocin, 95% CI, 1.21-1.62) but also was associated with successful VBAC. Maximum oxytocin dose was not associated with blood transfusion or ICU admission. Longer duration of any intrapartum oxytocin and longer duration at maximum oxytocin dose also were associated with higher odds of uterine rupture. CONCLUSION: Receipt of oxytocin at both lower and higher doses was associated with higher odds of uterine rupture across the full cohort when compared with no oxytocin exposure and also was associated with successful VBAC. Although a trend of increasing rupture with higher doses was observed, a maximum intrapartum higher dose (greater than 20 milli-international units/min) of oxytocin was not associated with uterine rupture when compared with lower dose. Thus, an upper safety threshold for maximum dose of oxytocin could not be identified.

来源:Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Bruno AM, Allshouse AA, Metz TD, et al. Maximum Oxytocin Dose and Uterine Rupture During Trial of Labor After Cesarean. Obstet Gynecol. 2025. PMID: 41325062. doi:10.1097/AOG.0000000000006106

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。